Previous independent reporting examining ColonBroom GLP-1 Booster explored the product's market entry, initial consumer reception, and formula positioning within the non-prescription metabolic support category
Villano G, Lunardi F, Turato C, Schiff S, Tono N, Campagna F, et al
A healthy gut microbiome with diversity produces short-chain fatty acids, causing GLP-1 release
At 24 weeks, retatrutide (1 mg, 4 mg, 8 mg or 12 mg) met the primary endpoint for efficacy in participants with obesity or overweight without diabetes
So we want their insulin sensitive
Tolerance protocols: Participants who couldnt tolerate Wegovys maintenance dose could simply lower their dosage